Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

Overview

Journal Cancer Discov

Specialty Oncology

Date 2016 Sep 30

PMID 27683556

Citations 173

Authors

Tanner M Johanns

Christopher A Miller

Ian G Dorward

Christina Tsien

Edward Chang

Arie Perry

Ravindra Uppaluri

Cole Ferguson

Robert E Schmidt

Sonika Dahiya

George Ansstas

Elaine R Mardis

Gavin P Dunn

Affiliations

Soon will be listed here.

Abstract

Significance: It is unclear whether hypermutated glioblastomas are susceptible to checkpoint blockade in adults. Herein, we provide proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation, leading to clinically and immunologically significant responses. These patients may represent a genomically stratified group for whom immunotherapy could be considered. Cancer Discov; 6(11); 1230-6. ©2016 AACR.See related commentary by Snyder and Wolchok, p. 1210This article is highlighted in the In This Issue feature, p. 1197.

Citing Articles

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.

Long G, Shklovskaya E, Satgunaseelan L, Mao Y, Pires da Silva I, Perry K Nat Med. 2025; .

PMID: 40016450 DOI: 10.1038/s41591-025-03512-1.

The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: A systematic review.

Schonfeld E, Choi J, Tran A, Kim L, Lim M Neurooncol Adv. 2024; 6(1):vdae174.

PMID: 39534539 PMC: 11555435. DOI: 10.1093/noajnl/vdae174.

On the Boundary of Exploratory Genomics and Translation in Sequential Glioblastoma.

Tompa M, Galik B, Urban P, Kajtar B, Kraboth Z, Gyenesei A Int J Mol Sci. 2024; 25(14).

PMID: 39062807 PMC: 11277311. DOI: 10.3390/ijms25147564.

Pathways to hypermutation in high-grade gliomas: Mechanisms, syndromes, and opportunities for immunotherapy.

Haynes T, Gilbert M, Breen K, Yang C Neurooncol Adv. 2024; 6(1):vdae105.

PMID: 39022645 PMC: 11252568. DOI: 10.1093/noajnl/vdae105.

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.

Richardson T, Walker J, Hambardzumyan D, Brem S, Hatanpaa K, Viapiano M Acta Neuropathol. 2024; 148(1):5.

PMID: 39012509 PMC: 11252228. DOI: 10.1007/s00401-024-02761-7.

References

Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

Hundal J, Carreno B, Petti A, Linette G, Griffith O, Mardis E . pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016; 8(1):11. PMC: 4733280. DOI: 10.1186/s13073-016-0264-5. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Adzhubei I, Jordan D, Sunyaev S . Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7.20. PMC: 4480630. DOI: 10.1002/0471142905.hg0720s76. View

Bouffet E, Larouche V, Campbell B, Merico D, De Borja R, Aronson M . Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. J Clin Oncol. 2016; 34(19):2206-11. DOI: 10.1200/JCO.2016.66.6552. View

Palles C, Cazier J, Howarth K, Domingo E, Jones A, Broderick P . Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2012; 45(2):136-44. PMC: 3785128. DOI: 10.1038/ng.2503. View

Kim J, Lee I, Cho H, Park C, Jung Y, Kim Y . Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015; 28(3):318-28. DOI: 10.1016/j.ccell.2015.07.013. View

Dunn G, Okada H . Principles of immunology and its nuances in the central nervous system. Neuro Oncol. 2015; 17 Suppl 7:vii3-vii8. PMC: 4625893. DOI: 10.1093/neuonc/nov175. View

McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9. PMC: 4984254. DOI: 10.1126/science.aaf1490. View

10.

Ding L, Ley T, Larson D, Miller C, Koboldt D, Welch J . Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382):506-10. PMC: 3267864. DOI: 10.1038/nature10738. View

11.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

12.

Kim H, Zheng S, Amini S, Virk S, Mikkelsen T, Brat D . Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015; 25(3):316-27. PMC: 4352879. DOI: 10.1101/gr.180612.114. View

13.

Spier I, Holzapfel S, Altmuller J, Zhao B, Horpaopan S, Vogt S . Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2014; 137(2):320-31. DOI: 10.1002/ijc.29396. View

14.

Erson-Omay E, Caglayan A, Schultz N, Weinhold N, Omay S, Ozduman K . Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro Oncol. 2015; 17(10):1356-64. PMC: 4578578. DOI: 10.1093/neuonc/nov027. View

15.

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

16.

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

17.

Landrum M, Lee J, Benson M, Brown G, Chao C, Chitipiralla S . ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2015; 44(D1):D862-8. PMC: 4702865. DOI: 10.1093/nar/gkv1222. View

18.

Miller C, White B, Dees N, Griffith M, Welch J, Griffith O . SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014; 10(8):e1003665. PMC: 4125065. DOI: 10.1371/journal.pcbi.1003665. View

19.

Frampton G, Fichtenholtz A, Otto G, Wang K, Downing S, He J . Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31(11):1023-31. PMC: 5710001. DOI: 10.1038/nbt.2696. View

20.

Alexandrov L, Nik-Zainal S, Wedge D, Aparicio S, Behjati S, Biankin A . Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-21. PMC: 3776390. DOI: 10.1038/nature12477. View